CLOs on the Move

Aulos Bioscience

www.aulosbio.com

 
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aulosbio.com
  • 245 main street Floor 12
    Cambridge, MA USA 02142
  • Phone: 617.294.6790

Executives

Name Title Contact Details

Similar Companies

Benjamin Biomedical Inc

Benjamin Biomedical Inc is a St Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atossa Genetics

Atossa Genetics is a healthcare company offering proprietary medical devices and laboratory services in women`s health. Our laboratory services are offered through our wholly owned subsidiary, the National Reference Laboratory for Breast Health (NRLBH)

Abpro

We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.

Poxel

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel`s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin`s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Allcells LLC

Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.